Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof

Abstract

The invention provides a sustained-release temperature-sensitive blood vessel embolic gel used for treating tumor. The sustained-release blood vessel embolic gel is prepared by entrapping a medicine by using a pharmaceutically acceptable carrier. The medicine is an anti-tumor medicine, and the pharmaceutically acceptable carrier comprises a gel prepared from poloxamer polymer, polyvinyl pyrrolidone, and the like or a composition thereof. The polymer material accounts for 5-65% of a gel mass. The particle size of the gel is in a range of 10nm to 150mum. The embolic agent is liquid gel under normal temperature, and can be used for direct injection through catheter. After injection into body, with the increase of temperature, the liquid gel is rapidly solidified into gel. Also, according to requirements, different medicines can be entrapped, and embolism and medication dual effect can be achieved through local sustained-release. Therefore, the gel provided by the invention can be used as an embolic agent for endovascular treatment, and can be used in various benign and malignant tumor transcatheter arterial chemoembolizations. The preparation method provided by the invention is simple, and is suitable for industrialized productions.

Description

Technical field: [0001] The present invention relates to pharmaceutical preparations, in particular to a drug-carrying gel drug carrier to construct a temperature-sensitive gel drug slow-release vascular embolism agent, in particular to a drug slow-release blood vessel embolism gel for treating tumors and a preparation method thereof . Background technique: [0002] At present, interventional therapy is one of the more popular and effective treatments for advanced tumors. In the interventional therapy, transcatheter arterial infusion chemotherapy (Transcatheter arterial infusion; TAI) and transcatheter arterial chemoembolization ( Transcatheter arterial chemoembolization; TACE) is most commonly used. A large number of experiments and clinical studies confirmed (HinoT, Kawashima Y, Shimabayashi S.Basic study for stabilization of w / o / w emulsion and its application to transcatheter arterial embolization therapy[J]. Adv Drug Deliv Rev, 2000, 45 (1) , 27-45.) Through selective ...

AI Technical Summary

Problems solved by technology

However, a large number of clinical and experimental studies have shown that iodized oil can only fill peripheral blood vessels, and is not an ideal embolic agent. It can be lost with the recanalization of blood vessels; whether it is a suspension or an emulsion, the drug is easy to precipitate or separate, and the slow-release effect Generally within 24-72 hours

Solid embolic agents such as gelatin sponge microspheres and PVA (polyvinyl alcohol) cannot be shaped according to the size and shape of blood vessels, and there are deficiencies such as incomplete embolization, induction of tumor neovascularization and collateral vessel formation

Other useful reports of Bletilla striata microsphere embolization agent, because Bletilla striata has a strong procoagulant effect in addition to mechanical obstruction, so its clinical efficacy is more reliable than other embolic agents, but due to its post-embolization pain, fever, liver function damage, etc. Serious side effects, currently not yet used clinically

Images